Zobrazeno 1 - 10
of 2 677
pro vyhledávání: '"Lerebours A"'
Autor:
François Bertucci, Arnaud Guille, Florence Lerebours, Michele Ceccarelli, Najeeb Syed, José Adélaïde, Pascal Finetti, Naoto T. Ueno, Steven Van Laere, Patrice Viens, Alexandre De Nonneville, Anthony Goncalves, Daniel Birnbaum, Céline Callens, Davide Bedognetti, Emilie Mamessier
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature reliably
Externí odkaz:
https://doaj.org/article/1068ae1848944ff180c01ffd49e76be5
Autor:
Mylène Duivon, Justine Lequesne, Antonio Di Meglio, Caroline Pradon, Ines Vaz-Luis, Anne-Laure Martin, Sibille Everhard, Sophie Broutin, Olivier Rigal, Chayma Bousrih, Christelle Lévy, Florence Lerebours, Marie Lange, Florence Joly
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer
Externí odkaz:
https://doaj.org/article/89577b2bd38749a3990b4d7af210ddbf
Autor:
François Bertucci, Florence Lerebours, Michele Ceccarelli, Arnaud Guille, Najeeb Syed, Pascal Finetti, José Adélaïde, Steven Van Laere, Anthony Goncalves, Patrice Viens, Daniel Birnbaum, Emilie Mamessier, Céline Callens, Davide Bedognetti
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of clinical IBC samples. Metho
Externí odkaz:
https://doaj.org/article/d411209f682649f3b4011eb089a7cbba
Autor:
Gilbert, Allison R., Caves Sivaraman, Josie, Lerebours, Reginald, Easter, Michele M., Siegel, Reah
Publikováno v:
In Journal of Criminal Justice January 2025 96
Autor:
Espanol, A., Lerebours, F., Calviere, L., Bonneville, F., Ducros, A., Larrue, V., Gollion, C.
Publikováno v:
In Revue Neurologique June 2024 180(6):486-493
Autor:
Tison, Thais, Loap, Pierre, Arnaud, Emilie, Cao, Kim, Bringer, Solene, Kissel, Manon, Maaradji, Safia, Mainguene, Juliette, Pierga, Jean-Yves, Lerebours, Florence, Vincent-Salomon, Anne, Mirabelle, Mariana, Bidard, Francois-Clement, Loirat, Delphine, Kirova, Youlia M.
Publikováno v:
In Advances in Radiation Oncology March 2024 9(3)
Autor:
Alvarez, Ofelia A., St Victor Dély, Nora, Paul Hanna, Michele, Saint Fleur, Rony, Cetoute, Marie, Metalonis, Sarah, Hustace, Tally, Brown, Eric C., Marcelin, Louis Herns, Muscadin, Emanise, Eveillard, Ronald, Lerebours, Emmeline
Publikováno v:
In Blood Advances 9 January 2024 8(1):14-22
Autor:
Garazi Ruiz de Azua, Isabelle Kousignian, Ines Vaz‐Luis, Antonio Di Meglio, Elsa Caumette, Julie Havas, Elise Martin, Anne‐Laure Martin, Ophelie Querel, Laurence Vanlemmens, Barbara Pistilli, Charles Coutant, Paul Henri Cottu, Asma Dhaini Merimeche, Florence Lerebours, Olivier Tredan, Christelle Jouannaud, Christelle Levy, Agnes Dumas, Gwenn Menvielle
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 19091-19101 (2023)
Abstract Purpose This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods We used data from the prospective French cohort, CANTO. We included 1811 stage I–III BCS who were 50 (OR = 0.59; 95%CI = 0.43–0.82),
Externí odkaz:
https://doaj.org/article/caaf22a6096241ad9f5aa1968c778c76
Autor:
D. Hequet, N. Hajjaji, E. Charafe‐Jauffret, A. Boucrauta, F. Dalenc, V. Nicolai, J. Lopez, O. Tredan, E. Deluche, V. Fermeaux, L. Tixier, A. Cayre, E. Menet, F. Lerebours, R. Rouzier
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16889-16895 (2023)
Abstract Background Genomic tests are a useful tool for adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive (HR+), and human epidermal growth factor receptor 2‐negative (HER2−) breast cancer with intermediate progno
Externí odkaz:
https://doaj.org/article/3d57135ebaa24cd780074539ea7c74e2
Autor:
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 3, Pp 101384- (2024)
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab. However, the safety
Externí odkaz:
https://doaj.org/article/3f2900b13cd74ba6b3f684249c69f513